Stock Markets May 6, 2026 10:50 AM

Amcor Shares Jump After Q3 Beat and Raised Fiscal 2026 Profit Forecast

Revenue outperformance, faster-than-expected Berry Global synergy delivery and an upgraded EPS outlook send stock higher amid broader market gains

By Maya Rios AMCR

Amcor shares climbed sharply after the packaging company reported third-quarter fiscal 2026 results that topped revenue expectations, matched adjusted EPS consensus, and lifted full-year adjusted EPS guidance. Management highlighted accelerated synergy capture from the Berry Global acquisition and declared a slightly higher quarterly dividend, while also revising free cash flow guidance lower due to elevated inventory and regional conflict impacts.

Amcor Shares Jump After Q3 Beat and Raised Fiscal 2026 Profit Forecast
AMCR

Key Points

  • Amcor reported adjusted EPS of $0.96, meeting analyst consensus, and revenue of $5.91 billion, above the $5.71 billion estimate and up 77% year-over-year.
  • The company raised fiscal 2026 adjusted EPS guidance to $3.98–$4.03 (midpoint $4.01), and recorded $77 million of acquisition synergies in the quarter, with $170 million year-to-date and an expectation of $270 million for the full year.
  • Amcor cut free cash flow guidance to $1.5–$1.6 billion from $1.8–$1.9 billion due to elevated inventory and impacts from the Middle East conflict; UBS reaffirmed a Buy rating.

Amcor stock surged in morning trading, rising 9.05% after the company released third-quarter fiscal 2026 results before the market opened. Investors responded to a revenue beat and an upward revision to the company's full-year adjusted earnings per share (EPS) outlook.

For the quarter, Amcor reported adjusted EPS of $0.96, in line with analyst consensus. Revenue reached $5.91 billion, exceeding the $5.71 billion estimate and representing a 77% increase from $3.33 billion in the same quarter a year earlier.

The company raised its fiscal 2026 adjusted EPS guidance to a range of $3.98 to $4.03. The midpoint of that range is $4.01, above the analyst consensus of $3.91.


Synergies and margin progress

Management emphasized the pace of synergy realization tied to the Berry Global acquisition as a central factor behind the stronger results. Amcor recorded $77 million of acquisition-related synergies during the quarter, reaching the upper bound of internal targets. Those cost efficiencies helped lift adjusted EBITDA margin to 15.1% from 14.3% a year earlier, as the company optimized its manufacturing footprint and consolidated corporate functions.

Year-to-date synergy capture reached $170 million. Amcor now expects total synergies for the full fiscal year 2026 to amount to $270 million.

"Executed a smooth integration, built a strong leadership structure, and made meaningful progress on synergy delivery and portfolio optimization."

Alongside the operational update, the board declared a quarterly dividend of $0.65 per share, a 2% increase versus the prior year.


Cash flow and operational headwinds

Amcor cautioned that it is continuing to manage the operational effects of the Middle East conflict. That dynamic has contributed to a downward revision in free cash flow guidance: the company now expects free cash flow of $1.5 to $1.6 billion for the year, reduced from a prior range of $1.8 to $1.9 billion. Management said the change reflects holding higher inventory levels at elevated cost in order to maintain customer service levels.


Sales composition and the role of acquisition growth

Net sales of $5,914 million were 70% higher than the prior-year quarter on a constant-currency basis. The company noted that the quarter included approximately $2.4 billion of acquired sales net of divestments, underscoring the material contribution of the Berry integration to top-line growth.


Market context and analyst response

The broader equity market provided a constructive backdrop on the day of the results. The S&P 500 rose 1.13% to 7,340.89, the Dow Jones Industrial Average gained 1.21% to 49,894.23, and the NASDAQ climbed 1.38% to 25,674.59. In parallel with the company update, UBS reaffirmed a Buy rating on Amcor, adding analyst support to the move in the stock.


Why the market moved

Investors responded to the combination of a material revenue beat, an upward revision to full-year EPS guidance, and accelerated synergy delivery from the Berry Global transaction. Those elements, together with a cooperative market environment, created a strong near-term catalyst for the stock’s outsized move.

At the same time, management flagged a reduction in expected free cash flow driven by higher inventory and regional conflict-related impacts, which introduces a cash-flow trade-off for the improved margin and revenue dynamics.


Bottom line

Amcor’s third-quarter fiscal 2026 report shows revenue growth substantially ahead of expectations, margin improvement tied to acquisition synergies, and an upgraded profit outlook for the year. The company balanced those positives with a tempered free cash flow forecast and commentary on operational risks stemming from geopolitical tensions and inventory decisions.

Risks

  • Geopolitical impacts: The Middle East conflict is affecting Amcor’s operations and contributed to a downward revision in free cash flow guidance, potentially affecting cash generation in the near term.
  • Inventory-related cash strain: Higher inventory levels held at elevated cost to secure customer service are lowering free cash flow expectations, introducing a trade-off between service levels and near-term cash conversion.
  • Integration execution risk: While management reported strong progress on Berry Global synergies to date, continued realization of the $270 million fiscal-year synergy target is necessary to sustain the margin benefits described.

More from Stock Markets

Warsaw equities finish higher as materials, construction and banking stocks lead gains May 6, 2026 Wealthfront Brings Digital Mortgage Service to Texas, Undercutting Average Rates May 6, 2026 Istanbul Stocks Climb to Record as Broad Rally Lifts BIST 100 May 6, 2026 Copenhagen Stocks Close Higher as Consumer and Chemical Names Lead Gains May 6, 2026 MannKind Shares Jump After United Therapeutics Collaboration on Ralinepag DPI May 6, 2026